外顯子組測序有助於新生兒先天性代謝缺陷的篩查
作者:
小柯機器人發布時間:2020/8/11 19:01:15
美國加州大學伯克利分校Steven E. Brenner、Aashish N. Adhikari和加州大學舊金山分校Jennifer M. Puck研究團隊,合作探究了外顯子組測序(WES)在新生兒先天性代謝缺陷(IEM)篩查中的應用。相關論文於2020年8月10日發表於《自然-醫學》雜誌。
研究人員獲取了2005年至2013年間在加利福尼亞出生的450萬嬰兒中幾乎所有IEM病例的存檔殘留幹血斑和數據,一些嬰兒在串聯質譜(MS / MS)篩查中呈陽性但後續測試為陰性。WES的整體靈敏度為88%,特異性為98.4%,而MS/MS分別為99.0%和99.8%,儘管各個IEM的效果各不相同。因此,對於大多數新生兒篩查(NBS) IEM而言,僅WES不夠靈敏或不適合作為主要篩選工具。
但是,作為對MS/MS篩查異常嬰兒的輔助檢查工具,WES可以減少假陽性結果、有助於及時解決病例,在某些情況下甚至可以提供比最初診斷更合適或更具體的診斷。這項研究是迄今為止受IEM影響的整個病例群體中最大的測序工作,從而可以無偏倚的評估WES作為種群篩選工具的可能。
據了解,NBS計劃可在人群中發現需要緊急幹預的罕見可治療疾病。當前MS/MS應用於篩查新生兒中一組罕見的IEM。
附:英文原文
Title: The role of exome sequencing in newborn screening for inborn errors of metabolism
Author: Aashish N. Adhikari, Renata C. Gallagher, Yaqiong Wang, Robert J. Currier, George Amatuni, Laia Bassaganyas, Flavia Chen, Kunal Kundu, Mark Kvale, Sean D. Mooney, Robert L. Nussbaum, Savanna S. Randi, Jeremy Sanford, Joseph T. Shieh, Rajgopal Srinivasan, Uma Sunderam, Hao Tang, Dedeepya Vaka, Yangyun Zou, Barbara A. Koenig, Pui-Yan Kwok, Neil Risch, Jennifer M. Puck, Steven E. Brenner
Issue&Volume: 2020-08-10
Abstract: Public health newborn screening (NBS) programs provide population-scale ascertainment of rare, treatable conditions that require urgent intervention. Tandem mass spectrometry (MS/MS) is currently used to screen newborns for a panel of rare inborn errors of metabolism (IEMs)1,2,3,4. The NBSeq project evaluated whole-exome sequencing (WES) as an innovative methodology for NBS. We obtained archived residual dried blood spots and data for nearly all IEM cases from the 4.5 million infants born in California between mid-2005 and 2013 and from some infants who screened positive by MS/MS, but were unaffected upon follow-up testing. WES had an overall sensitivity of 88% and specificity of 98.4%, compared to 99.0% and 99.8%, respectively for MS/MS, although effectiveness varied among individual IEMs. Thus, WES alone was insufficiently sensitive or specific to be a primary screen for most NBS IEMs. However, as a secondary test for infants with abnormal MS/MS screens, WES could reduce false-positive results, facilitate timely case resolution and in some instances even suggest more appropriate or specific diagnosis than that initially obtained. This study represents the largest, to date, sequencing effort of an entire population of IEM-affected cases, allowing unbiased assessment of current capabilities of WES as a tool for population screening.
DOI: 10.1038/s41591-020-0966-5
Source: https://www.nature.com/articles/s41591-020-0966-5